Abstract |
Leishmania donovani GP36 glycoprotein is the main antigen of the FML Fucose Mannose Ligand ( FML) complex specifically recognized by sera of kala-azar human patients. The GP36 was isolated by chemical elution + sonication and used for Balb/c mouse vaccination in combination with saponin, by the s.c. route, inducing a strong and specific protective effect against experimental visceral leishmaniasis shown by the increase of: specific IgG antibodies (82.6%), mainly IgG2a, the delayed type of hypersensitivity to promastigote lysate (37.8%, P < 0.001), the in vitro cellular proliferative response to GP36 of ganglia lymphocytes (53.5%, P < 0.005) and the decrease of liver parasite burden (68.1%, P < 0.025). Saponin treated controls reacted significantly differently from GP36 vaccinated animals at all the assayed variables (P < 0.05). GP36 induced significant protection against murine visceral leishmaniasis at concentrations commonly used for vaccination with recombinant antigens.
|
Authors | E Paraguai de Souza, R R Bernardo, M Palatnik, C B Palatnik de Sousa |
Journal | Vaccine
(Vaccine)
Vol. 19
Issue 23-24
Pg. 3104-15
(Apr 30 2001)
ISSN: 0264-410X [Print] Netherlands |
PMID | 11312005
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Antibodies, Protozoan
- Antigens, Protozoan
- Protozoan Proteins
- Protozoan Vaccines
|
Topics |
- Animals
- Antibodies, Protozoan
(biosynthesis)
- Antigens, Protozoan
(administration & dosage, isolation & purification)
- Female
- Immunity, Cellular
- Leishmania donovani
(immunology)
- Leishmaniasis, Visceral
(immunology, prevention & control)
- Mice
- Mice, Inbred BALB C
- Protozoan Proteins
(administration & dosage, immunology, isolation & purification)
- Protozoan Vaccines
(administration & dosage)
|